Taro Pharmaceutical Industries to acquire Alchemee from Galderma

Taro Pharmaceutical Industries, a multinational, science-based pharmaceutical company, and Swiss-based Galderma have signed a definitive agreement for Taro to acquire Alchemee, formerly The Proactiv Company, from Galderma. The agreement includes Alchemee’s business and assets around the world, including the Proactiv® brand.

The acquisition is subject to customary closing conditions and any necessary regulatory approvals. Financial terms of the transaction have not been disclosed.

Lenz & Staehelin is advising Taro on Swiss law matters. The team is led by partners Matthias Wolf and Tino Gaberthüel (both m&a, pictured above) and includes partner Pascal Hinny, associate Lukas Aebi (both tax) and associate Alex Wille (m&a).